The impact of obesity on inflammatory markers used in the assessment of disease activity in rheumatoid arthritis - a cross-sectional study.

INTRODUCTION: Obesity is known to be associated with elevated levels of inflammatory markers. The aim of the study was to assess the confounding effect of obesity on the levels of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in patients with rheumatoid arthritis (RA) in low disease activity state or remission as indicated by clinical disease activity index (CDAI).
MATERIAL AND METHODS: Adult RA patients with CDAI less than 10 were divided into two groups: obese and non-obese, based on body mass index. Relevant exclusions were applied to eliminate causes of raised inflammatory markers other than obesity. The difference of CRP and ESR levels between the obese and non-obese groups was analyzed.
RESULTS: Obese patients with RA (n = 85) had higher CRP and ESR than non-obese patients (n = 66) (p-values 0.008 and 0.000005, respectively). In addition, obese females with RA had significantly higher CRP and ESR as compared to non-obese females. However, the difference was not significant in males. Twenty-one obese (24.7%) and two non-obese RA patients (3%) had elevated CRP (difference of approximately 22% [24.7 minus 3]). Forty obese (47%) and 16 non-obese RA patients (24.2%) had elevated ESR (difference of approximately 23% [47 minus 24.2]). Thus, obesity was the attributable cause of falsely elevated CRP and ESR in 22% and 23% of patients, respectively.
CONCLUSIONS: About one-fifth of patients with RA, who are actually in low disease activity, may have elevated inflammatory markers, primarily because of obesity. Therefore, elevated CRP and ESR in obese patients with RA should be interpreted with caution because it may lead to unnecessary overtreatment. Copyright:

Introduction

Rheumatoid arthritis (RA) is a systemic inflammatory disorder in which raised C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) suggest active disease. Acute phase reactants are also used in monitoring the patients with RA, to assess the response to treatment. Studies have shown that obesity is positively correlated with raised CRP and ESR in the general population [1, 2]. Acute phase reactants also rise in response to infection and inflammation. They constitute important components of various composite indices for measuring disease activity of RA. Obesity can falsely raise acute phase reactants in obese patients with RA, independent of disease activity [3]. This can lead to falsely high scores of various disease activity tools, which incorporate acute phase reactants, thereby making the true assessment of disease activity difficult.

Published literature shows evidence of correlation of inflammatory markers and obesity in patients with RA, independent of disease activity. None of the studies described the frequency of this confounding effect. We conducted this study to assess how often obesity causes a confounding effect on the raised inflammatory markers in patients with RA in low disease activity state or remission.

The primary objective was to study the frequency of the confounding effect of obesity on the levels of CRP and ESR in patients with rheumatoid arthritis in low disease activity state or remission, using the clinical disease activity index (CDAI). The effect of gender on CRP and ESR levels in RA patients was also studied as a secondary objective.

Material and methods

Adult RA patients (2010 American College of Rheumatology criteria) aged more than 18 years and with CDAI < 10 (CDAI is the sum of the number of tender joints, number of swollen joints, physician global assessment [0 to 10], and patient global assessment [0 to 10]) were recruited into the study from January 2018 to December 2018, after obtaining informed consent [4, 5]. A sample size of 144 subjects (type I error 5% and type II error 20%, Z-value 1.96, confidence level 95%) was obtained with the assumption that elevation of CRP and ESR attributable to obesity would occur in at least 10% of patients with RA in low disease activity state/remission (as defined by CDAI). Low disease activity was defined by CDAI of 2.8 to 9 and remission at CDAI below 2.8.

Patients were divided into two groups: group A comprised obese RA patients defined by a body mass index (BMI) of > 25 [6]. Group B comprised non-obese RA patients (BMI < 25). A third control group comprising obese individuals without RA was also included in the study. CRP levels and ESR were obtained on all study subjects. CRP (in milligrams per liter; mg/l) was measured by nephelometry and ESR (in millimeters per hour; mm/h) by Westergren’s method.

Exclusions comprised patients with any evidence of infection currently or in the past month, major surgery in the past three months, another inflammatory disorder (e.g. interstitial lung disease, chronic obstructive pulmonary disease, scleritis/episcleritis, rheumatoid vasculitis, overlap with another connective tissue disease), pregnancy, anemia (hemoglobin < 10 g/dl), current smoking, polycythemia, sickle cell anemia, liver disease, or malignancy. Patients treated with tocilizumab were excluded from this analysis; patients treated with all other biologic disease-modifying antirheumatic drugs (DMARDs) were included in the study if they were having remission or low disease activity state. Abatacept is not available in India anymore, so none of our patients were treated with this drug.

It was a cross-sectional study. However, study groups were not matched for age and gender. Statistical significance of the difference of CRP and ESR levels between groups A and B, between group A and controls, and between group B and controls was analyzed by Mann-Whitney U test. Statistical significance was set at p ≤ 0.05

Informed consent was obtained from patients included in the study, and ethical clearance was obtained from our hospital’s institutional review board. Date of approval: 27th August 2019, No. ECR/TH/2019/04.

Results

Eighty-five obese RA patients (12 males [M], 73 females [F]), 66 non-obese RA patients (17 M, 49 F), and 52 obese controls (16 M, 36 F) were recruited into the study (Table I).

Table I

Baseline characteristics

Parameters	Obese RA(n = 85)	Non-obese RA(n = 66)	Obese controls(n = 52)
Mean age (years)	55.165	51.061	48.1
Number of males (%)	12 (14.1)	17 (25.8)	16 (30.8)
Number of females (%)	73 (85.9)	49 (74.2)	36 (69.2)
Mean disease duration (months)	110.75	74.9
Mean BMI (kg/m2)	29.5	21.6	33.5
Median CDAI (IQR)	0 (5)	0 (4)
Median CRP (IQR)	5 (5.7)	3 (3)	3.45 (7.2)
Median ESR (IQR)	30 (21)	18 (19.5)	20.5 (20)
Mean CDAI (SD)	2.53 (3.16)	2.07 (2.8)
Mean CRP (SD)	9.9 (13.01)	4.7 (7.96)	5.4 (4.26)
Mean ESR (SD)	30.7 (17.13)	20.4 (13.01)	25.7 (17.43)

RA – rheumatoid arthritis, BMI – body mass index, CDAI – clinical disease activity index, IQR – interquartile range, CRP – C-reactive protein, ESR – erythrocyte sedimentation rate, SD – standard deviation.

Among all female patients with RA (n = 122), 91 were post-menopausal (74.5%). Mean BMI was 29.5, 21.6, and 33.5 kg/m2 in the three groups, respectively. Obese and non-obese RA patients had median CDAI of 0 (IQR 5 and 4, respectively). Fifty-two obese RA patients (61.1%) and 43 non-obese RA patients (65.1%) were in remission (Fig. 1). Median CRP levels in the 3 groups were 5 (IQR 5.7), 3 (IQR 3) and 3.45 (IQR 7.2) respectively and median ESR was 30 (IQR 21), 18 (IQR 19.5) and 20.5 (IQR 20) respectively. Obese patients with RA had mean CRP of 7.82 (95% confidence interval 7.82 ±1.82) and mean ESR of 32.8 (95% confidence interval 32.8 ±3.73). Non-obese patients with RA had mean CRP of 3.88 (95% confidence interval 3.88 ±0.74) and mean ESR of 21.19 (95% confidence interval 21.19 ±3.45). Among patients with RA, obese patients had significantly higher CRP and ESR than non-obese patients (p-values 0.008 [effect size 0.2984] and 0.000005 [effect size 0.3466], respectively) (Fig. 2). The difference in CRP level between obese RA patients and obese controls was not significant (p-value 0.2 [effect size 0.283]).

Fig. 1

Disease activity state in patients with rheumatoid arthritis (RA).

Fig. 2

A – C-reactive protein (CRP) levels in patients with rheumatoid arthritis (RA), B – erythrocyte sedimentation rate (ESR) values in patients with RA, C – CRP levels in female patients with RA, D – CRP levels in male patients with RA, E – ESR values in female patients with RA, F – ESR values in male patients with RA.

The difference in CRP and ESR between obese and non-obese RA patients was not significant for males (p-value 0.964 [effect size 0.0815] and 0.051 [effect size 0.2841], respectively), unlike for females (p-value 0.008 [effect size 0.324] and 0.0001 [effect size 0.34], respectively) (Fig. 2). CRP levels did not differ significantly between males and females in the three groups. The same was true for ESR in obese RA and non-obese RA patients. In contrast, the difference in ESR between females and males in the obese control group just reached statistical significance (median 21.5 and 16, respectively; p-value 0.048 [effect size 0.2384]).

Twenty-one obese RA patients (24.7%) and two non-obese RA patients (3%) had CRP levels more than 10 mg/l (difference of approximately 22% between the two groups [24.7 minus 3]). Similarly, 40 obese RA patients (47%) and 16 non-obese RA patients (24.2%) had ESR more the 30 mm/hour (difference of approximately 23% between the two groups [47 minus 24.2]). Thus, obesity contributed to falsely elevated CRP and ESR in 22% and 23% of patients with RA, respectively (Fig. 3).

Fig. 3

Percentage of rheumatoid arthritis (RA) patients having C-reactive protein (CRP) more than 10 mg/l (A) and erythrocyte sedimentation rate (ESR) more than 30 mm/h (B).

Discussion

The present study showed that obese patients with RA had a significantly higher CRP and ESR than non-obese RA patients. When CRP of obese RA patients with low disease activity/remission was compared with that of obese non-RA controls, there was no significant difference. Here the CRP elevation was accounted by obesity mainly. Interestingly, obesity was not associated with significantly higher CRP and ESR in males with RA in our study.

George et al. [3] reported similar observations, in which they showed that CRP and ESR positively correlated with obesity in females with RA but not in males. It was a large study in which the association of CRP and ESR with obesity was studied in two RA cohorts and a control cohort without RA. Dual-energy X-ray absorptiometry (DEXA) was used to assess the truncal fat mass. Positive correlation between CRP and BMI was found in females with and without RA. Similar correlation was found between ESR and BMI in females. The association between CRP and BMI vanished when fat mass was adjusted, thus confirming that CRP correlated mainly with fat mass. Adipose tissue is a site for synthesis of many mediators of inflammation, including interleukin 6 (IL-6) [7]. This leads to an increase in acute phase reactants in obese individuals. Weight loss due to inflammation because of active disease was hypothesized by George et al. to be the cause of poor association of CRP and ESR with BMI in men with RA [3].

Testosterone seems to have an inhibitory effect on CRP because lower CRP levels are found in males with higher testosterone levels [8].

Fat around internal organs (visceral fat) has a greater effect on CRP synthesis by liver, as compared to truncal fat. In all the previous studies, truncal fat was estimated by DEXA. Assessment of visceral fat by computed tomography (CT) of the abdomen may remove the discrepancy between obesity and acute phase reactants observed in males with RA.

Among the anthropometric parameters, waist circumference has been shown to correlate most closely with CRP in the healthy population [9]. This is also true in patients with RA, independent of disease activity [10]. Higher levels of CRP and IL-6 were found in women with RA with a higher BMI and truncal fat measured by DEXA [11]. In the same study, treatment with biological drugs did not alter the positive correlation between CRP and truncal fat. In addition, a similar correlation between obesity and IL-6 levels was observed, as with CRP.

None of the studies mentioned above included patients in low disease activity or remission. However, adjustment for disease activity was made in these studies. We took patients in low disease activity or remission, to effectively rule out active disease as a cause for the raised acute phase reactants. However, subclinical inflammation might be present in some patients, which could have contributed to raised CRP or ESR. Ultrasound or magnetic resonance imaging can detect subclinical inflammation [12, 13].

The confounding effect of obesity on inflammatory markers is not well studied in patients with other rheumatic diseases. However, Oeser et al. [14] showed that obese patients with SLE had significantly higher levels of CRP and ESR.

Raised markers of inflammation should be interpreted with caution in obese patients with RA, because it can have implications on the treatment. In addition, obese patients tend to report higher scores of subjective disease activity [15]. These factors may result in unnecessary overtreatment of many obese patients by a “treat-to-target” approach due to falsely high disease activity scores on the composite indices dependent on acute phase reactants and patients’ global assessment. In the current era, where there are multiple options for the treatment of RA, judicious use of drugs is necessary to avoid overtreatment.

We recruited patients with RA with low disease activity or remission, thereby eliminating disease activity as the cause for elevated CRP or ESR. Moreover, using strict exclusion criteria, we eliminated other potential contributors to elevated inflammatory markers and excluded patients treated with tocilizumab because it has a direct effect of reduction in the levels of CRP by reducing its synthesis in liver. One limitation of our study was the lack of objective assessment of fat mass by DEXA or visceral fat mass (by CT abdomen). It is noteworthy that imaging techniques for assessment of body fat do not have standardized definitions for obesity.

Conclusions

Obesity may falsely elevate CRP and ESR in as many as 22% and 23%, respectively, of RA patients with low disease activity. Clinicians should be cautious while treating RA patients with a “treat-to-target” approach, in which composite disease activity indices utilizing acute phase reactants as one of their components are used. In the current era, when there are multiple options for the treatment of RA (including biological DMARDs), judicious use of drugs is necessary to avoid overtreatment.